|Bid||105.00 x 900|
|Ask||105.59 x 1100|
|Day's Range||105.11 - 106.68|
|52 Week Range||72.88 - 115.49|
|Beta (5Y Monthly)||0.39|
|PE Ratio (TTM)||17.48|
|Earnings Date||Feb 02, 2023|
|Forward Dividend & Yield||2.92 (2.77%)|
|Ex-Dividend Date||Mar 14, 2023|
|1y Target Est||116.96|
Subscribe to Yahoo Finance Plus to view Fair Value for MRK
Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 10th of April to...
RAHWAY, N.J., January 27, 2023--FDA Approves KEYTRUDA as Adjuvant Treatment Following Surgical Resection and Chemotherapy for Patients With Stage IB (T2a ≥4 cm), II, or IIIA NSCLC
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.